A bipartisan group of senators urged the FDA to amend 2018 guidance for biosimilar products in order to expedite approvals of cheaper, generic insulin products, arguing that it is "unacceptable that -- nearly a century after insulin was first discovered -- there are no approved, lower-cost insulin products that can be substituted at the pharmacy level." The US has only three insulin manufacturers, and the drug's price doubled on average from 2012 to 2016.
Lawmakers call on FDA to expedite generic insulin approvals
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.